UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Validation of the Korean Version of the EORTC QLQ-C30

Quality of life research, 2004-05, Vol.13 (4), p.863-868

2004

Volltextzugriff (PDF)

EP-1082: Involved-site radiotherapy based on FDG-PET/CT after R-CHOP chemotherapy in diffuse large B cell lymphoma

Radiotherapy and oncology, 2014, Vol.111, p.S14-S14

2014

Volltextzugriff (PDF)

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

European journal of cancer (1990), 2016-12, Vol.69, p.S135-S136

2016

Volltextzugriff (PDF)

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E376-E376

2016

Volltextzugriff (PDF)

EP-1070: Outcome of radiotherapy in intracranial germinoma at basal ganglia/thalamus

Radiotherapy and oncology, 2014, Vol.111, p.S9-S10

2014

Volltextzugriff (PDF)

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.47-47

2012

Volltextzugriff (PDF)

EP-1040 REDUCED-DOSE RADIOTHERAPY BY THE CHEMORESPONSIVENESS FOR THE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Radiotherapy and oncology, 2012-05, Vol.103, p.S407-S407

2012

Volltextzugriff (PDF)

EP-1052 RADICAL CHEMORADIOTHERAPY AS A TREATMENT OF CHOICE FOR THE ELDERLY WITH LOCALLY ADVANCED NSCLC

Radiotherapy and oncology, 2012-05, Vol.103, p.S411-S411

2012

Volltextzugriff (PDF)

AOS10 Prognostic factors for patients with leptomeningeal metastases from solid tumours

European journal of cancer (1990), 2012-04, Vol.48, p.S6-S7

2012

Volltextzugriff (PDF)

Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2022-10, Vol.174, p.S110-S111

2022

Volltextzugriff (PDF)

Antibiotic use during the last days of life in cancer patients

European journal of cancer care, 2006-03, Vol.15 (1), p.74-79

2006

Volltextzugriff (PDF)

Treatment strategies based on the molecular subtypes of transformed small cell lung cancer (t-SCLC)

European journal of cancer (1990), 2022-10, Vol.174, p.S120-S120

2022

Volltextzugriff (PDF)

EP-1149 Albumin-to-alkaline phosphatase ratio in nasopharyngeal cancer: a propensity score matching analysis

Radiotherapy and oncology, 2019-04, Vol.133, p.S637-S637

2019

Volltextzugriff (PDF)

EP-1165 Failure Patterns of Cervical Lymph Nodes in Metastases of Unknown Primary according to Target Volume

Radiotherapy and oncology, 2019-04, Vol.133, p.S645-S645

2019

Volltextzugriff (PDF)

Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC

Annals of oncology, 2017-09, Vol.28, p.v472-v473

2017

Volltextzugriff (PDF)

EP-1166 Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer

Radiotherapy and oncology, 2019-04, Vol.133, p.S645-S646

2019

Volltextzugriff (PDF)

Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

Annals of oncology, 2019-10, Vol.30, p.v628

2019

Volltextzugriff (PDF)

1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

Annals of oncology, 2019-10, Vol.30, p.v628-v628

2019

Volltextzugriff (PDF)

8727 Outcome after high-dose methotrexate and radiotherapy for primary central nervous system lymphoma

European journal of cancer supplements, 2009, Vol.7 (2), p.501-501

2009

Volltextzugriff (PDF)

A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma

Annals of oncology, 2016-10, Vol.27, p.vi487-vi487

2016

Volltextzugriff (PDF)

414 - Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

European journal of cancer (1990), 2016-12, Vol.69, p.S135-S136

2016

Volltextzugriff (PDF)

OA11.05 Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S346-S347

2018

Volltextzugriff (PDF)

P1.01-60 Prognostic Impact of PD-L1 Expression on EGFR Tyrosine Kinase Inhibition in Lung Adenocarcinoma

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S381-S382

2019

Volltextzugriff (PDF)

P2.04-42 PD-L1-Mediated Enhancement of Hexokinase 2 Expression Is Inversely Related to T-Cell Effector Gene Expression in Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S724-S725

2019

Volltextzugriff (PDF)

MA11.07 Expression of LAG-3 and NY-ESO-1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S394-S394

2018

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(57)
Tagungsberichte
(2)

Sprache

Englisch
(56)
Koreanisch
(3)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Validation of the Korean Version of the EORTC QLQ-C30

EP-1082: Involved-site radiotherapy based on FDG-PET/CT after R-CHOP chemotherapy in diffuse large B cell lymphoma

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

EP-1070: Outcome of radiotherapy in intracranial germinoma at basal ganglia/thalamus

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

EP-1040 REDUCED-DOSE RADIOTHERAPY BY THE CHEMORESPONSIVENESS FOR THE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EP-1052 RADICAL CHEMORADIOTHERAPY AS A TREATMENT OF CHOICE FOR THE ELDERLY WITH LOCALLY ADVANCED NSCLC

AOS10 Prognostic factors for patients with leptomeningeal metastases from solid tumours

Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)

Antibiotic use during the last days of life in cancer patients

Treatment strategies based on the molecular subtypes of transformed small cell lung cancer (t-SCLC)

EP-1149 Albumin-to-alkaline phosphatase ratio in nasopharyngeal cancer: a propensity score matching analysis

EP-1165 Failure Patterns of Cervical Lymph Nodes in Metastases of Unknown Primary according to Target Volume

Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC

EP-1166 Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer

Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)

8727 Outcome after high-dose methotrexate and radiotherapy for primary central nervous system lymphoma

A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma

414 - Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

OA11.05 Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)

P1.01-60 Prognostic Impact of PD-L1 Expression on EGFR Tyrosine Kinase Inhibition in Lung Adenocarcinoma

P2.04-42 PD-L1-Mediated Enhancement of Hexokinase 2 Expression Is Inversely Related to T-Cell Effector Gene Expression in Non-Small-Cell Lung Cancer

MA11.07 Expression of LAG-3 and NY-ESO-1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC

Aktive Filter

Suchergebnisse filtern